Regeneron Reports Third Quarter 2020 Financial and Operating Results
The Pharma Data
NOVEMBER 5, 2020
Corporate and Business Development Update. In July 2020 , the Company announced an agreement whereby the Company was awarded a $450 million contract to manufacture and supply REGN-COV2 to the U.S. Cost of collaboration and contract manufacturing (COCM). $. Expenses: Research and development.
52 
Let's personalize your content